Previous Article | Next Article ![]()
Eukaryotic Cell, November 2008, p. 1880-1887, Vol. 7, No. 11
1535-9778/08/$08.00+0 doi:10.1128/EC.00222-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

and
Joseph V. Gray1*
Molecular Genetics and Integrative & Systems Biology, Faculty of Biomedical and Life Sciences, University of Glasgow, Anderson College Complex, 56 Dumbarton Road, Glasgow G11 6NU, United Kingdom,1 Banting and Best Department of Medical Research, University of Toronto, 112 College Street, Toronto, Ontario M5G 1L6, Canada2
Received 7 July 2008/ Accepted 9 September 2008
|
|
|---|
|
|
|---|
The small GTPase Rho1 is central to the CWI pathway. Rho1-GTP directly binds to and activates multiple effectors, including the Fks1/2 glucan synthases, the Bni1/Bnr1 formins, and the exocyst component Sec3 (22). One key and direct target is Pkc1, the only Saccharomyces cerevisiae homolog of mammalian protein kinase C and an essential protein required for the maintenance of cell integrity (21).
The CWI pathway is stimulated by a variety of intrinsic and extrinsic signals transduced via a variety of upstream branches (22). Many of these signals, e.g., heat shock and cell wall perturbations, are detected via their effect on the cell surface as sensed by the multiple members of the WSC family of cell surface sensors (11, 15, 38). These putative mechano-sensors bind to and activate the Rho guanine nucleotide exchange factors (GEFs) Rom2 and Tus1 to activate Rho1 (28, 32). However, upstream signaling is even more complex, with multiple additional branches feeding information into the pathway. Some signals are transduced via Rho1 regulators but independently of the WSC sensors, e.g., TOR signaling modulates the Rho1 GEF Rom2 (33), CDK1/Cdc28 directly phosphorylates the Rho1 GEF Tus1 (19), and the mRNA binding protein Mpt5 inhibits expression of the Rho1 GTPase-activating protein Lrg1 (34). Finally, actin cytoskeletal defects appear to be sensed by an unknown mechanism independent of both the WSC sensors and known Rho1 regulators (12).
Here, we focus on the Pkc1 hub of the CWI pathway. Pkc1 controls multiple downstream branches, the best understood of which is the mitogen-activated protein (MAP) kinase cascade terminating in the Slt2 MAP kinase. This cascade is not essential under normal conditions but is required for cells to survive stresses such as high temperature. Slt2 is known to directly activate, among others, the Rlm1 and Swi4 transcription factors, which are important for expression of genes involved in cell surface construction (1, 41).
We set out to identify new regulators and components of the CWI/Pkc1 pathway. We chose a genetic strategy. Synthetic lethal genetic interactions, a type of phenotype enhancement, occur when two loss-of-function mutations in different genes cause lethality but only when present together. Such interactions can now be systematically uncovered in yeast for any given "query" mutation by using synthetic genetic array (SGA) analysis (36) or diploid-based synthetic lethality analysis with microarrays (27). Although synthetic genetic interactions tend to occur between genes in parallel "buffering" pathways or processes, mutations in essential genes are thought to preferentially sensitize an organism to a second mutation that affects the same rather than a parallel process (26).
Here, we determined the set of mutations in nonessential genes (null mutations) that confer hypersensitivity to lowered Pkc1 activity via a novel modification of SGA analysis, dominant-negative SGA (DN-SGA) analysis. We find that most of the corresponding 21 genes are closely and functionally linked to the CWI pathway, including the uncharacterized YDL203c/ACK1 gene, which encodes a new upstream modulator of basal CWI activity.
|
|
|---|
Oligonucleotides. The following primers were used (Sigma-Aldrich): Ack1F (5'-GAATTCGATATCAAGCTTATCGATACCGTCGACAATGGTTAATCAGGGCCAACC-3'), Ack1R (5'-GCGTAGCATAACTAATTACATGACTCGAGGTCGACTTAATTTGTCAAACTTCGAAGAGC-3'), Tus1F (5'-GAATTCGATATCAAGCTTATCGATACCGACAATGTATCGATATAATTAGAAGTTCCCCT-3'), and Tus1R (5'-GCGTAGCATAACTAATTACATGACTCGAGGTCGACTTATTGATGATCTGCCATTGCT-3'). The identities of many haploid deletion strains were confirmed by PCR amplification at the replacement locus, using the KanB primer and the appropriate gene-specific "Primer A" flanking primer according to the Yeast Knockout Consortium (http://www-sequence.stanford.edu/group/yeast_deletion_project/confirmation.html).
Strains, genetic crosses, and plasmids.
Most of the S. cerevisiae strains used are derived from the BY4741 or BY4742 yeast strain of the S288c strain background. For the DN-SGA screen, the query strain was MAT
Mfa1
::MFA1pr-HIS3 can1
his3
leu2
ura3
MET15+ lys2
transformed with pGAL1-PKC1(dead). We obtained the wild-type BY4741 strain, with the genotype MATa his3
1 leu2
met15
ura3
(Euroscarf), along with its derivative single null mutations api2
::KanMX4, atg15
::KanMX4, bck1
::KanMX4, bni1
::KanMX4, chl1
::KanMX4, cik1
::KanMX4, csf1
::KanMX4, ctf19
::KanMX4, egd1
::KanMX4, jnm1
::KanMX4, las21
::KanMX4, mid1
::KanMX4, mig1
::KanMX4, opi3
::KanMX4, ost3
::KanMX4, per1
::KanMX4, rom2
::KanMX4, sec28
::KanMX4, spa2
::KanMX4, swi4
::KanMX4, tus1
::KanMX4, ump1
::KanMX4, and ydl203c
::KanMX4. We also obtained the wild-type strain BY4742, with the genotype MAT
his3
1 leu2
lys2
ura3
, and the homozygous wsc1
/
diploid mutant MATa/MAT
his3
1/his3
1 leu2
/leu2
met15
/MET15 LYS2/lys2
ura3
/ura3
wsc1
::KanMX4/wsc1
::KanMX4 in the same strain background (Euroscarf). A deletion, marked with NatMX, in the TUS1 gene was generated in the query strain as described by Tong et al. (36). The temperature-sensitive mutant of PKC1, stt1-1, was in the W303 strain background (MATa ura3
leu2
trp1
his3
ade2
can1-100) (43). The homozygous slt2
/
strain was in the EG123 strain background (MATa/MAT
trp1
/trp1
leu2
/leu2
ura3
/ura3
his4
/his4
can1
/can1
) (11).
All genetic backcrosses were made to congenic wild-type cells of the opposite mating type. Haploid rom2
tus1
cells were generated by standard genetic manipulations from a cross between tus1::NatMX4 and rom2::KanMX4 haploid strains.
The plasmids used in this study include pGAL-PKC1, pGAL-PKC1(dead), and 2µPKC1 (DL289) plasmids (40); pROM2-HA and pSLT2-HA (33); pROM2-GFP and pTUS1-GFP (44); and pMKK1 (14).
pACK1 and pTUS1 were generated by inserting the respective genes into the vector, pGREG535 (Euroscarf), by homologous recombination. This vector contains a GAL1,10 promoter and a hemagglutinin tag. The vector was digested with SalI to remove its HIS+ marker. PCR amplified genes (using Ack1F and Ack1R or Tus1F and Tus1R) were cotransformed with SalI-digested pGREG535 into BY4741 yeast cells. Transformants were selected on SD-Leu plates. Plasmid DNA from five independent yeast colonies was transformed into XL1-Blue Escherichia coli cells (Stratagene). Plasmid DNA was purified, and the presence and orientation of an insert were confirmed by restriction digestion. The function of the plasmids was confirmed by in vivo complementation of the relevant null-mutant phenotypes.
DN-SGA analysis.
DN-SGA analysis was performed as previously described for SGA analysis (36, 37), but with the following modifications. The chromosomal copy of PKC1 was left unaltered in the query strain (Y4115). Instead, the wild-type "query" strain was transformed with a URA3-marked plasmid [pGAL-PKC1(dead)] expressing a dominant-negative allele of PKC1 encoding a catalytically inactive full-length protein [Pkc1(dead)] expressed under the control of the inducible GAL1,10 promoter. The transformed query strain was crossed to the arrayed haploid deletion collection (
4,700 viable null mutants) in glucose-containing medium lacking uracil. Subsequent sporulation and selection for transformed haploid progeny yielded an arrayed collection of haploid deletion mutants, each containing pGAL-PKC1(dead). This arrayed collection was subsequently pinned to SGalactose-URA medium, and transformants that proliferated poorly, if at all, after 1 day on this inducing medium were identified. The analysis was repeated twice, and any mutants that grew poorly, if at all, upon induction of Pkc1(dead) in at least two of the three independent runs were considered to be positives.
Determination of staurosporine sensitivity. The sensitivity of each strain to the Pkc1 inhibitor staurosporine was determined as follows. Cells were cultured overnight in YPD (untransformed cells) at room temperature and supplemented with sorbitol (1 M) when appropriate. Cultures were diluted into fresh medium and incubated with agitation for 6 h at room temperature. Culture density was adjusted to an optical density at 600 nm (OD600) of 0.05. Aliquots (100 µl) were placed in the wells of a sterile 96-well microtiter plate, and staurosporine (or vehicle alone as a control) was added. The plates were incubated at room temperature overnight with gentle agitation. The final OD600 of each culture was determined using a plate reader. The analysis was performed at least six times.
Determination of sensitivity to tunicamycin, calcofluor white, chlorpromazine, and benomyl. Mutants and their congenic wild-type cells were grown in YPD or synthetic medium to mid-logarithmic phase. The cultures were diluted to an OD600 of 0.02, and serial dilutions into fresh medium were made. Samples (5 µl) of each dilution were spotted onto fresh plates with or without tunicamycin (1.5 µg/ml), calcofluor white (150 µg/ml), chlorpromazine (200 µg/ml) (Calbiochem), or benomyl (20 µg/ml). The plates were incubated for 2 to 3 days at 25°C.
Quantifying Rlm1-dependent reporter activity. Cells were transformed with a LacZ reporter construct, pRLM1-LacZ (17). Transformed cells were cultured to mid-logarithmic phase in SD-URA at room temperature, and β-galactosidase activity was quantified in Miller Units by the standard protocol according to Stewart et al. (34). During estimation of stress induction of CWI signaling, transformed cells were treated with calcofluor white (150 µg/ml), chlorpromazine (200 µg/ml), or latruculin B (40 µg/ml) for 3 h at 25°C prior to the β-galactosidase assay. All assays were performed in triplicate on three separate days. The relative reporter activity for each mutant was calculated relative to the level for untreated congenic wild-type cells assayed on the same day.
|
|
|---|
DN-SGA analysis.
We transformed the wild-type query strain with a marked plasmid expressing the catalytically inactive allele of PKC1 [pkc1(dead)] under the control of the galactose-inducible GAL1,10 promoter (40). The transformed query strain was crossed with the arrayed haploid deletion collection, resulting in arrayed, transformed haploid mutant progeny generated by standard SGA methodology (36). The
5,000 arrayed transformants were then transferred onto medium containing galactose as the sole carbon source (inducing condition), and the growth of the each spot was noted. The sixty-six transformants that grew poorly or not at all on galactose-containing medium in two or three of three independent runs were taken to constitute the set of primary mutants identified by the analysis.
Mutants were eliminated from further analysis when any of the following applied: (i) the untransformed mutants were unable to proliferate on galactose as the sole carbon source, thereby eliminating gal mutants; (ii) sensitivity to expression of Pkc1(dead) was not reproduced upon direct transformation; or (iii) mutants were sensitive to expression of wild-type Pkc1 driven from an equivalent pGAL-PKC1(WT) construct, thereby eliminating those sensitive to overexpression of the protein rather than to lowered activity. In all, 29 mutants survived the triage and behaved as reproducibly sensitive only to the induction of Pkc1(dead) expression.
Confirmation of genetic interactions: staurosporine sensitivity.
We wished to independently confirm the genetic interactions with PKC1. Staurosporine is a broad-spectrum protein kinase inhibitor that preferentially inhibits isozymes of protein kinase C (35). Pkc1 appears to be the limiting target of staurosporine in yeast (40, 43). Indeed, the sensitivity of wild-type cells to staurosporine, like the inviability of pkc1
mutants, is suppressed by osmotic stabilization (Fig. 1A and data not shown). Furthermore, pretreatment with staurosporine abolishes activation of CWI signaling upon challenge with stress (S. A. Krause and J. V. Gray, unpublished observation). We found that 28 of the 29 robust mutants identified by DN-SGA analysis are also hypersensitive to staurosporine. This hypersensitivity cosegregated with the marked deletion in at least 10 tetrads for 21 of the 28 cases in genetic backcrosses, consistent with the idea that these mutations cause sensitivity to lowered Pkc1 activity. The identity of the knockout in each strain was successfully confirmed by PCR. These 21 mutants constitute the PKC1 interaction network (Table 1).
![]() View larger version (28K): [in a new window] |
FIG. 1. Chemical-genetic analysis indicates that two-thirds of the PKC1 genetic interaction network comprises "within-pathway" interactions. (A) Example of sorbitol suppression of the hypersensitivity of a null mutant to staurosporine. Wild-type and api2 cells were grown in rich medium and then diluted into wells of a 96-well plate containing fresh medium supplemented with staurosporine (range, 0 µg/ml to 50 µg/ml). The cells were incubated either in the presence (+) or in the absence (–) of sorbitol (1 M). (B) Scheme illustrating the functional classification of the PKC1-interacting genes. Fourteen of the genes behave as encoding proteins that act in the Pkc1 pathway (staurosporine sensitivity is suppressed by osmotic stabilization), six of which encode known CWI pathway components (see text). The remaining seven genes behave as encoding proteins that function, at least in part, parallel to Pkc1 (staurosporine sensitivity is not suppressed by osmotic stabilization).
|
|
View this table: [in a new window] |
TABLE 1. Confirmed genes that are members of the PKC1 network
|
|
View this table: [in a new window] |
TABLE 2. Chemical sensitivities of null mutants in the PKC1 interaction network
|
Chemical-genetic epistasis test.
Are the other 15 genes closely linked to CWI signaling? To begin to address this question, we exploited a unique property of pkc1
mutants: inviability is suppressed in high-osmolarity medium, a condition that is thought to physically stabilize the fragile mutant cells (22). Pathway activity is thus not required for cell viability under this condition. High osmolarity does not completely bypass the requirement for the kinase: Pkc1 is still required for growth at a high temperature, even under this condition.
We reasoned that mutations that affect the Pkc1 pathway/process would not enhance the phenotype caused by loss of Pkc1 activity when in osmotically stabilized medium at room temperature. Pathway activity is not required under this condition, and hence, mutations affecting another pathway component cannot further exacerbate the phenotypes of mutants with lowered or no Pkc1 activity. Osmotic stabilization should thus suppress the synthetic genetic interaction with PKC1 noted for normal media. In contrast, mutations that affect a parallel process should enhance pkc1 defects in both the absence and the presence of osmotic stabilization, as has previously been noted for the BRO1 gene (25).
We tested all 21 mutants. We found that 1 M sorbitol suppresses the staurosporine hypersensitivity of two-thirds of the mutants (Fig. 1A and B), thereby functionally linking the corresponding gene products to Pkc1. This chemical-genetic test of functional relatedness is highly specific: all six mutants that lack a known component of the pathway fall into this "within-pathway" class (Fig. 1B).
The majority of interacting genes encode inhibitors of CWI signaling. What functional relationships may link interacting gene products to Pkc1 function? Some gene products may function as inhibitors of CWI signaling. Mutants lacking such proteins could be defective in processes to which the CWI pathway responds, e.g., cell wall construction, with the resulting elevation in pathway activity acting to ameliorate the consequences of the mutations.
We estimated CWI pathway activity in the 21 null mutants by using an established transcriptional reporter in which expression of the bacterial LacZ gene is dependent on the Rlm1 transcription factor (17). This reporter faithfully reflects the activity state of the Pkc1-MAP kinase pathway (17). We found that the majority of mutants (12/21) display high basal Rlm1-LacZ reporter activity (Fig. 2). The mutants with the highest basal reporter activity (>3 times that of wild-type cells) point to the best-known triggers of and roles for CWI signaling: las21
, per1
, and ost3
are defective in cell wall/surface synthesis (2, 7, 18), and bni1
is (and api2
is thought to be) defective in actin organization/cell morphogenesis (3, 6). A novel trigger is suggested by the high reporter activity seen for opi3
mutants. This mutant lacks a phospholipid methyltransferase required for phosphatidylcholine (PC) synthesis (23). The CWI pathway may thus also respond to changes in PC levels, complementing the established role of Pkc1 in directly phosphorylating enzymes involved in PC synthesis (4, 42).
![]() View larger version (13K): [in a new window] |
FIG. 2. The basal activity of the Rlm1-LacZ reporter construct is altered in the majority of the Pkc1 genetic network. Each of the 21 network mutants, along with the congenic wild-type strain, was transformed with a plasmid containing LacZ expressed under the control of the Slt2-dependent transcription factor Rlm1. The transformed mutants were assayed for β-galactosidase activity. The relative activity was determined in comparison to the activity of wild-type transformed cells. The experiment was performed on multiple different days and in triplicate on each day. Data from each day were scaled to the average data for the wild-type controls on that day. The average relative activities of the mutants across days and the standard deviations are shown for each mutant. The relative activity for wild-type cells is 1.0 by definition.
|
Some interacting genes encode activators of CWI signaling.
Some of the remaining genes in the PKC1 network may encode activators of CWI signaling. Mutants lacking such proteins would have low pathway activity, rendering them hypersensitive to further reduction. In total, four mutants displayed low basal Rlm-LacZ reporter activity, consistent with compromised CWI signaling: bck1
, egd1
, ctf19
, and ydl203c
(Fig. 2). BCK1 encodes the known MAP kinase kinase kinase that is absolutely required for activity of Slt2 and Rlm1. Rlm1-LacZ reporter activity is minimal in this mutant (<2% of wild-type levels). EGD1 encodes a subunit of the nascent polypeptide-associated complex (30). CTF19, a gene regulated by the CWI pathway (31), encodes a protein involved in accurate mitotic chromosome segregation (13). Both egd1
and ctf19
mutants display modest reductions in reporter activity (
81% and
66% of wild-type levels, respectively). Egd1 and Ctf19 may be novel activators of CWI signaling, but their roles remain to be clarified. Finally, mutants lacking the uncharacterized YDL203c gene display substantial reductions in reporter gene activity (down to
25% of wild-type levels).
Ydl203c/Ack1 is a novel upstream activator of Pkc1.
Loss of YDL203c results in low Rlm1-LacZ reporter activity. The staurosporine hypersensitivity of ydl203c
is suppressed by sorbitol, supporting a role for Ydl203c in the CWI/Pkc1 pathway (Fig. 1B and data not shown). If Ydl203c is indeed important for CWI signaling, then mutants lacking the protein should display an appropriate phenotype. The mutants are not temperature sensitive for growth but are hypersensitive to tunicamycin treatment (Table 2 and data not shown).
If Ydl203c is a bona fide regulator of CWI signaling, then we expect its overproduction or activation to stimulate reporter activity. Indeed, we find that overexpression of YDL203c in wild-type cells elevates Rlm1-LacZ reporter activity by approximately twofold (Fig. 3A).
![]() View larger version (13K): [in a new window] |
FIG. 3. Ydl203c/Ack1 activates Rlm1-LacZ reporter activity but is not required for stress induction of the reporter. (A) Wild-type cells were cotransformed with the Rlm1-LacZ reporter plasmid and either a vector control or a plasmid expressing YDL203c under a GAL1,10 promoter. The transformed cells were grown in synthetic medium containing galactose and sucrose to induce the expression of YDL203c. The transformed cells were assayed for β-galactosidase activity. The experiment was performed in triplicate. The relative activity was determined relative to the average activity of the vector controls analyzed on the same day. Standard deviations for the replicates are shown for each strain. (B) Wild-type and yld203c cells transformed with the Rlm1-LacZ reporter construct were examined for their ability to activate the expression of the reporter construct. Overnight cell cultures were diluted and treated with or without 150 µg/ml calcofluor white (CW), 200 µg/ml chlorpromazine (CPZ), or 40 µg/ml latrunculin B (LatB) for 3 hours prior to the assay for β-galactosidase activity. The activity was determined relative to that for untreated, wild-type cells, and all analyses were performed in triplicate on the same day. Standard deviations for replicates are shown for each strain.
|
mutant? We assayed activation of reporter activity in wild-type and ydl203c
mutants upon cell surface stresses (calcofluor white or chlorpromazine treatment) or upon actin depolymerization (latrunculin B treatment). We find that the reporter is efficiently activated in the mutant and upon each of the treatments tested (Fig. 3B). Ydl203c is therefore not required for the transduction of cell surface or actin cytoskeleton defects to the CWI pathway. Activation of the reporter activity upon latrunculin B treatment is, however, less efficient than that upon treatment with the cell surface stressors, indicating that Ydl203c may preferentially enhance this input. Overall, the protein appears to selectively affect the amount of CWI signaling under both basal and induced conditions.
If Ydl203c indeed acts in the Pkc1 pathway, then epistatic analysis should specify a point of action for the protein. We undertook two complementary analyses. First, we examined if activation or overexpression of known pathway components, ranging from the upstream Rom2 and Tus1 Rho1 GEFs to the downstream Slt2 MAP kinase, could suppress the tunicamycin sensitivity of ydl203c
mutants. We found that activation or overexpression of all the corresponding genes can efficiently suppress the mutant defect, consistent with the idea that Ydl203c acts at or upstream of the Rho1 GEFs in the pathway (Fig. 4A and B). Second, we examined if overexpression of YDL203c can suppress the defects of mutants defective at various levels of the pathway. We found that overexpression of the gene efficiently suppresses the defects of rom2
and tus1
mutants and wsc1
/wsc1
mutants lacking a major upstream sensor but not the defects of pkc1ts or slt2
/slt2
mutants lacking key downstream components. These data point to the possibility that Ydl203c acts in the Pkc1 pathway and at or upstream of Pkc1 (Fig. 4C and D). We rename the gene ACK1 (activator of C kinase 1).
![]() View larger version (21K): [in a new window] |
FIG. 4. Epistasis analysis places Ydl203c/Ack1 in the Pkc1 pathway and upstream of Pkc1. (A) ydl203c cells were transformed with plasmids overexpressing ROM2, TUS1, PKC1, MKK1, or SLT2 and a vector control. Transformed cells were grown in synthetic medium, diluted to an OD600 of 0.02, and then serially diluted into fresh medium. The dilutions were spotted onto synthetic medium plates containing tunicamycin (Tm; 1.5 µg/ml). The plates were incubated at 25°C for 2 days, and the growth of transformants was compared to that for the vector control. "+" indicates growth better than that for the vector control. (B) Example of suppression of the tunicamycin hypersensitivity of ydl203c cells by overexpression of ROM2. (C) wsc1 /wsc1 , rom2 , tus1 , pkc1ts, slt2 / , and rom2 tus1 cells and their congenic wild-type cells were transformed with a vector control or a plasmid expressing YDL203c under a GAL1,10 promoter. The transformed cells were streaked onto synthetic medium plates containing galactose and sucrose to induce the expression of YDL203c. Plates were incubated at 25°C, and a duplicate set was incubated at 37°C to examine the ability of Ydl203c to suppress the temperature sensitivity of pkc1ts, slt2 / , and rom2 tus1 cells. Plates containing benomyl (20 µg/ml) were used to assess the ability of YDL203c overexpression to suppress the benomyl hypersensitivity of rom2 and rom2 tus1 cells. Plates containing chlorpromazine (200 µg/ml) were used to examine the ability of YDL203c overexpression to suppress the chlorpromazine hypersensitivity of tus1 cells. Plates containing calcofluor white (25 µg/ml) were used to examine the ability of YDL203c overexpression to suppress the calcofluor white hypersensitivity of wsc1 /wsc1 cells. All plates were incubated at 25°C for 2 days before the growth of the transformants was assessed. "+" indicates growth better than that of the vector control transformants; "–" indicates growth equal to that of the vector control. (D) Example of the ability of YDL203c overexpression to suppress the benomyl hypersensitivity of rom2 cells. Wt, wild type.
|
Does Ack1 act via the Rho1 GEFs? Our genetic analysis indicates that Rom2 activity is not wholly dependent on Ack1 and vice versa: overexpression of one suppresses the defect caused by the absence of the other. The same holds for Tus1 and Ack1. There are two possible explanations. First, Ack1 may act independently of the two main Rho1 GEFs to stimulate Pkc1 activity. Second, Ack1 may act via both Rho1 GEFs, with the activity of neither being wholly dependent on Ack1. If the former model applies, then ACK1 should affect CWI signaling even in the absence of both Rom2 and Tus1; if the latter applies, then ACK1 function would be abolished in the absence of these two Rho1 GEFs. We constructed rom2
tus1
double mutant haploids by standard genetic manipulations. We found that the double mutant is viable in our strain background but is temperature sensitive and hypersensitive to benomyl. We found that overexpression of ACK1 is unable to suppress any of the defects tested for rom2
tus1
double mutants (Fig. 4 and data not shown). Whatever its role, Ack1 is a novel upstream activator of CWI-Pkc1 signaling and functionally dependent on the Rho1 GEFs.
|
|
|---|
DN-SGA analysis has two strengths. Because the query allele is plasmid borne and hence extrachromosomal, it is not genetically linked to any chromosomal locus (16). The entire genome is thus surveyed in the approach. Second, because lethality is dependent on the conditional expression of the dominant-negative query allele, the terminal phenotype associated with each synthetic lethal interaction can be easily determined. For example, most of the synthetic lethal interactions with PKC1 reported here are accompanied by increased cell lysis, consistent with the idea that a cell integrity defect underlies the majority of these interactions (S. A. Krause and J. V. Gray, unpublished observations). DN-SGA analysis extends the range of alleles that are amenable to systematic genetic analysis and should be a useful addition to the genetic arsenal.
The genetic interaction network around PKC1. The synthetic lethal network around PKC1 is rich in genes functionally and closely linked to Pkc1. All of the 21 null mutants display the appropriate chemical sensitivities (Table 2). An independent chemical-genetic epistasis test places two-thirds of the genes within the functional envelope of Pkc1 (Fig. 1), of which six encode known components of the CWI pathway. We confirm that another gene, YDL203c/ACK1, encodes a novel modulator of the pathway (see below). Our findings are consistent with the long-held expectation that genetic enhancements of hypomorphic alleles efficiently enrich for mutations affecting the same pathway or biological process (26).
If the synthetic lethal network around PKC1 preferentially identifies components of the CWI pathway, why are all the known components of the pathway not represented in the network? There are multiple possible reasons. First, some components, like Rho1, are essential and not covered by this analysis. Second, some components are redundant, e.g., Mkk1 and Mkk2, where mutation of either gene alone causes little or no phenotypic change. Third, many components may be involved in branches and processes that do not contribute to the essential role(s) of Pkc1. Fourth, many components may contribute preferentially to an activated rather than to the basal state of the pathway. Only mutations affecting basal activity will be identified under the nonstressed conditions examined here. Finally, although SGA analysis and its derivatives are systematic and genome-wide, they suffer a high rate of false negatives (36). Such genetic screens are not fully saturating.
Functional relationships underlying the genetic network. Here, we also probed the likely functional relationships that underlie the genetic interactions with PKC1. We estimated Pkc1 pathway activity in each mutant by using an Rlm1-LacZ reporter, a faithful indicator of Pkc1-Slt2 activity state (17). We thereby identified three distinct subgroups within the PKC1 network. We consider each in turn.
We found that the majority (12/21) of mutants in the PKC1 network display high basal reporter activity, consistent with the idea that such mutants cause defects to which the Pkc1 pathway responds. These mutants would be particularly dependent on Pkc1 activity if this high activity were required to ameliorate the phenotypic consequences of the mutations. Such behavior is expected for signaling pathways that affect cell viability and that are under negative-feedback control. Both conditions apply to the Pkc1/CWI pathway: the overall pathway is essential and is known to be under feedback control by the activity state of the nonessential, downstream MAP kinase module (22). Our data point to the possibility that feedback control is more extensive and also embraces the Bni1 and Mig1 branches.
Six of the mutants display normal basal reporter activity, suggestive of normal Pkc1 pathway activity, as assessed by the activity of an Slt2-Rlm1-dependent reporter. Such mutants could be deficient in any branch of the pathway other than the MAP kinase branch that controls the Rlm1-LacZ reporter. In addition, the CWI pathway activity (as assessed by reporter gene activity) must not be under feedback control in response to loss of these gene products: activity remains normal. Alternatively, these mutants may be deficient in some process or pathway that acts in parallel to the CWI pathway and whose absence is again not surveyed by the pathway. Examples of both types appear to be represented in this mutant class: the chemical-genetic epistasis test (Fig. 1) places three of the six proteins within the envelope of Pkc1 function. Two of these are known components of the pathway: Spa2 and Mid1. Spa2 is important for proper localization of the Slt2 MAP kinase, but this localization is not important for activation of the Rlm1 transcription factor by Slt2. Mid1 is a putative calcium channel lying on a separate branch relative to the MAP kinase module, leaving Slt2-Rlm1 communication fully intact.
Finally, four null mutants display compromised reporter activity, suggestive of low Pkc1-Slt2-Rlm1 activity. Such mutants could be hypersensitive to reduction in Pkc1 activity because the activity of Pkc1 (as assessed by an Slt2-Rlm1-dependent reporter) in unstressed mutants is closer to the minimal threshold activity of the kinase required to support cell viability. These mutants should lack positively acting components of the pathway. Indeed, all four genes behave in a chemical-genetic epistasis test as part of the Pkc1 pathway (Fig. 1). The mutant with the lowest reporter activity lacks Bck1, a kinase known to be required for communication between Pkc1 and Slt2. In contrast, mutants lacking EGD1 and CTF19 display only a modest reporter defect. The relationships between Edg1 and Ctf19 and CWI signaling are not as yet established, although CTF19 is a transcriptional target of the pathway (31). The fourth mutant, lacking YDL203c/ACK1, displays an intermediate reporter defect. We find that this gene indeed encodes a novel activator of CWI signaling (see below).
Ack1 is a new upstream component of the Pkc1 pathway.
Multiple lines of evidence place the uncharacterized protein Ydl203c/Ack1 in the Pkc1 pathway. First, ack1
mutants are hypersensitive to lowered Pkc1 activity. Second, this hypersensitivity is efficiently suppressed by osmotic stabilization (Fig. 1), placing Ack1 function within the envelope of Pkc1 in vivo activity. Third, the CWI pathway is compromised in ack1
mutants: the mutants display low Rlm1-LacZ reporter activity (Fig. 2) and are hypersensitive to tunicamycin (Table 2), and this hypersensitivity is suppressed by overexpression of many pathway components (Fig. 4A). Fourth, overexpression of ACK1 is sufficient to stimulate CWI pathway activity: overexpression is sufficient to suppress the defects of some mutants defective in upstream signaling (Fig. 4C) and to elevate basal Rlm1-LacZ reporter activity (Fig. 3A). Finally, standard epistasis analysis places Ack1 within the pathway and indicates that it acts upstream of Pkc1 (Fig. 4).
We do not yet fully understand how Ack1 modulates CWI signaling. The protein has been found in complex with the Rho1 GEFs Rom2 (8, 9) and Tus1 (8). Indeed, our genetic analysis indicates that both Rom2 and Tus1 are required for Ack1 to affect CWI signaling: overexpression of ACK1 can suppress the defects of rom2
and tus1
mutants but not those of the double mutant (Fig. 4C). Ack1 may thus be a modulator of or a scaffold for Rho1 GEF complexes. Whatever its role, it does not appear to grossly alter the stability of the proteins or their subcellular localization (S. A. Krause and J. V. Gray, unpublished observations). Our investigations are ongoing.
Ack1 is clearly important for setting activity level of the pathway but does not appear to be required for gross activation of the pathway in response to cell surface or cytoskeletal defects (Fig. 3B). Whatever its mode of action, Ack1 joins an ever increasing number of components, including the PUF protein Mpt5 (34) and the ubiquitination enzyme Ubp3 (39), that point to unanticipated complexity in setting and modulating pathway activity.
This work was supported by research grants C20144 [GenBank] and BB/E011632 from the Biotechnology and Biological Sciences Research Council (J.V.G.).
Published ahead of print on 19 September 2008. ![]()
Present address: Molecular Oncology and Breast Cancer Program, BC Cancer Research Centre, 675 West 10th Avenue, Vancouver, British Columbia V5Z 1L3, Canada. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»